FDA approves monthly subcutaneous olanzapine LAI Weltruza, expanding schizophrenia treatment options and renewing debate on making long-acting injectables routine.
|Videos|March 10, 2021
Promising Publication: The Novel Schizophrenia Treatment Gaining Traction
Author(s)Stephen Brannan, MD
Data published in The New England Journal of Medicine shows promise for a novel schizophrenia treatment.
Advertisement
Stephen Brannan, MD, Chief Medical Officer of Karuna Therapeutics, talks more on the phase II clinical data for KarXT, published in the
To read more, see
Dr Brannan is chief medical officer at Karuna Therapeutics and a neuroscience drug development expert.
Advertisement
Related to this article
Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
2
Reframing “Treatment-Resistant” as “Difficult-To-Treat”
3
Formulations Matter: The Approval of Olanzapine Extended-Release Injectable Suspension for Schizophrenia
4
Relief Is Not Free: A Case Study of Athlete Cannabis Use
5